Imaging tumor angiogenesis using [18F]-DCFPyL PET/CT in patients with colon, gastric and pancreatic cancer.

MC0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•Patients aged 18 years or older.
•Diagnosis of primary T3-4N0-2M0-1 colorectal adenocarcinoma (cohort 1), primary T3-4N0-
•2M0 gastric carcinoma (cohort 2), or suspected pancreatic ductal adenocarcinoma (cohort 3)
•and eligible for surgery.
•Before patient registration, written informed consent must be given according to ICH/GCP,
•and national/local regulations.

•Women who are pregnant and/or or lactating.
•Medical or psychiatric conditions that compromise the patient’s ability to give informed
•consent. Presence of any psychological, familial, sociological or geographical condition
•potentially hampering compliance with the study protocol and follow-up schedule.
•Prior radiotherapy to the abdomen (cohort 1, 2 and 3) and/or thorax (cohort 2 and 3).
•Unacceptable known (clinically significant) cardiovascular or pulmonary disease, renal or liver
•dysfunction, which could hamper participation in this study or jeopardize the patients’ health.
•Known hypersensitivity to drugs comparative to DCFPYL, or any of their excipients or to any
•component of [18F]-DCFPYL.
•Inability to undergo PET/CT scanning (e.g. claustrophobia, weight limits or inability to tolerate
•lying for the duration of a PET/CT scan (~30 min).
•Inability to undergo routine MRI or CT scans as part of the diagnostic work up.

发起方